- Details
- Description
-
Packaging Size56c/bottles
-
Strength3mg
-
CompositonTunlametinib
-
TreatmentAdvanced melanoma harboring NRAS mutations
-
Formcapsule
-
Brand科露平
-
Quantity Unit3mg*56c/Box
-
ManufacturerShanghai KeChow Pharma, Inc.,China
Tunlametinib (HL-085) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor, for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas.
- Tunlametinib sold under the brand name 科露平® in china.
March 18, 2024, China’s National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy.